As of May 21
| -0.60 / -2.53%|
The 8 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 23.00, with a high estimate of 31.00 and a low estimate of 17.00. The median estimate represents a -0.43% decrease from the last price of 23.10.
The current consensus among 9 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.